Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Food Funct ; 11(12): 10423-10435, 2020 Dec 01.
Article in English | MEDLINE | ID: mdl-33237043

ABSTRACT

Management of abdominal pain, a common symptom of IBDs and IBS, is still a clinical problem. Extra virgin olive oil (EVOO), a main component of the Mediterranean diet, shows positive effects on chronic inflammation in IBDs. In this study, the effect of the oral administration of EVOO (3 mL) and two olive milling by-products, DPA (300 mg kg-1) and DRF (300 mg kg-1), on preventing the development of abdominal pain in a DNBS-induced colitis model in rats was evaluated. The doses were chosen with the aim of simulating a plausible daily intake in humans. DPA and EVOO treatments significantly reduced the abdominal viscero-motor response to colon-rectal distension at 2 and 3 mL of balloon distension volume, both 7 and 14 days after the DNBS-injection. DRF showed efficacy in the reduction of visceral hypersensitivity only with 3 mL balloon inflation. In awake animals, DPA and DRF reduced pain perception (evaluated as abdominal withdrawal reflex) with all balloon distension volumes, while EVOO was effective only with higher distension volumes. Fourteen days after the DNBS-injection, all samples reduced the macroscopic intestinal damage (quantified as the macroscopic damage score) also showing, at the microscopic level, a reduction of the inflammatory infiltrate (quantified by hematoxylin and eosin analysis), fibrosis (highlighted by picrosirius red staining), the increase in mast cells and their degranulation (analyzed by triptase immunohistochemistry). This is the first report on the promotion of abdominal pain relief in a rat model obtained administering EVOO and two derived by-products. Our results suggest a protective role of phenol-rich EVOO and milling by-products, which may be proposed as food ingredients for novel functional foods.


Subject(s)
Abdominal Pain/drug therapy , Gastrointestinal Diseases/drug therapy , Olea/chemistry , Olive Oil/therapeutic use , Phenols/therapeutic use , Animals , Colitis/chemically induced , Colitis/drug therapy , Colon/pathology , Diet, Mediterranean , Dinitrofluorobenzene/adverse effects , Dinitrofluorobenzene/analogs & derivatives , Disease Models, Animal , Functional Food , Inflammation , Male , Olive Oil/chemistry , Phenols/analysis , Plant Oils , Rats , Rats, Sprague-Dawley
2.
Int J Mol Sci ; 21(12)2020 Jun 17.
Article in English | MEDLINE | ID: mdl-32560291

ABSTRACT

The management of chronic visceral pain related to Inflammatory Bowel Diseases or Irritable Bowel Syndrome is still a clinical problem and new therapeutic strategies continue to be investigated. In the present study, the efficacy of a pomegranate decoction and of its polysaccharide and ellagitannin components in preventing the development of colitis-induced abdominal pain in rats was evaluated. After colitis induction by 2,4-dinitrobenzenesulfonic acid (DNBS), the pomegranate decoction (300 mg kg-1), polysaccharides (300 mg kg-1), and ellagitannins (45 mg kg-1) were orally administered for 14 days. Repeated treatment with decoction reduced visceral hypersensitivity in the colitic animals both at 7 and 14 days. Similar efficacy was shown by polysaccharides, but with lower potency. Ellagitannins administered at dose equivalent to decoction content showed higher efficacy in reducing the development of visceral pain. Macroscopic and microscopic evaluations performed on the colon 14 days after the damage showed that all three preparations reduced the overall amount of mast cells, the number of degranulated mast cells, and the density of collagen fibers in the mucosal stroma. Although ellagitannins seem to be responsible for most of the beneficial effects of pomegranate on DNBS-induced colitis, the polysaccharides support and enhance its effect. Therefore, pomegranate mesocarp preparations could represent a complementary approach to conventional therapies for promoting abdominal pain relief.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Colitis/complications , Plant Extracts/pharmacology , Pomegranate/chemistry , Visceral Pain/etiology , Animals , Anti-Inflammatory Agents/chemistry , Biomarkers , Disease Models, Animal , Immunohistochemistry , Plant Extracts/chemistry , Rats , Retreatment , Treatment Outcome , Visceral Pain/diagnosis , Visceral Pain/drug therapy
3.
Nutrients ; 12(1)2019 Dec 20.
Article in English | MEDLINE | ID: mdl-31861862

ABSTRACT

Abdominal pain is a frequent symptom of irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBDs). Although the knowledge of these pathologies is progressing, new therapeutic strategies continue to be investigated. In the present study, the effect of a system of molecules of natural origin (a medical device according to EU Directive 93/42/EC, engineered starting from Boswellia serrata resins, Aloe vera polysaccharides and Matricaria chamomilla and Melissa officinalis polyphenols) was evaluated against the intestinal damage and visceral pain development in DNBS-induced colitis model in rats. The system (250 and 500 mg kg-1) was orally administered once daily, starting three days before the injection of 2,4-dinitrobenzenesulfonic acid (DNBS) and for 14 days thereafter. The viscero-motor response (VMR) to colon-rectal balloon distension (CRD) was used as measure of visceral sensitivity. The product significantly reduced the VMR of DNBS-treated animals. Its effect on pain threshold was better than dexamethasone and mesalazine, and not lower than amitriptyline and otilonium bromide. At microscopic and macroscopic level, the tested system was more effective in protecting the intestinal mucosa than dexamethasone and mesalazine, promoting the healing of tissue lesions. Therefore, we suggest that the described system of molecules of natural origin may represent a therapeutic option to manage painful bowel diseases.


Subject(s)
Abdominal Pain/drug therapy , Plant Preparations , Resins, Plant , Visceral Pain/drug therapy , Aloe/chemistry , Animals , Chamomile/chemistry , Colitis/drug therapy , Disease Models, Animal , Flavonoids , Male , Rats , Rats, Sprague-Dawley
4.
J Pharm Pharmacol ; 71(6): 971-981, 2019 Jun.
Article in English | MEDLINE | ID: mdl-30784067

ABSTRACT

OBJECTIVES: The creation of a new valid preclinical model of articular pain by the intra-articular (i.a.) injection of mucilages for the screening of new treatments against arthritis. METHODS: A single intra-articular injection (20 µl) of mucilages (from Althaea officinalis roots and Linum usitatissimun seeds) or vegetal components (Amorphophallus konjac gum powder and ß-glucan, used as reference standard) were assessed in the rat. The pathology progression was monitored by behavioural measurements (paw pressure test, von Frey test, incapacitance test and beam balance test) and compared to that induced by the i.a. injections of monoiodioacetate (MIA) and Complete Freund's Adjuvant (CFA), well-recognized models of osteoarthritis and rheumatoid arthritis, respectively. KEY FINDINGS: Among all, the mucilage of L. usitatissimun showed the best pro-algic profile inducing a painful long-lasting condition. Hypersensitivity was characterized as a mixed form of inflammatory and neuropathic pain by the responsiveness to ibuprofen (100 mg/kg, p.o.) and pregabalin (30 mg/kg, p.o.). The histological evaluation of joint showed a damage that represents both MIA and CFA features. CONCLUSIONS: In conclusion, a single i.a. injection of L. usitatissimun mucilage can represent a valid model to assess articular pain in the rat for the screening of new treatments against arthritis.


Subject(s)
Arthritis, Experimental/pathology , Arthritis, Rheumatoid/pathology , Osteoarthritis/pathology , Plant Mucilage/toxicity , Althaea/chemistry , Analgesics/pharmacology , Animals , Arthritis, Experimental/drug therapy , Arthritis, Rheumatoid/drug therapy , Flax/chemistry , Freund's Adjuvant/toxicity , Ibuprofen/pharmacology , Injections, Intra-Articular , Male , Neuralgia/drug therapy , Neuralgia/etiology , Osteoarthritis/drug therapy , Pain/drug therapy , Pain/etiology , Plant Mucilage/administration & dosage , Pregabalin/pharmacology , Rats , Rats, Sprague-Dawley
SELECTION OF CITATIONS
SEARCH DETAIL